Last reviewed · How we verify

NCT04911322

Pulmonary Artery Doppler and Neonatal Outcome in Placenta Accreta Spectrum Patients

Completed Last updated 7 September 2022
What this trial tests

trial testing ultrasonography in Placenta Accreta in 71 participants. Completed in 1 September 2022.

Timeline
15 August 2021
Primary endpoint
1 August 2022
1 September 2022

Quick facts

Lead sponsorCairo University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment71
Start date15 August 2021
Primary completion1 August 2022
Estimated completion1 September 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 18 to 42, female only, with Placenta Accreta. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To correlate ultrasonographic markers of fetal lung maturity including Pulmonary artery Doppler indices in the late preterm and early term in placenta accreta spectrum patients with neonatal outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ultrasonography

Trials testing the same drug.

Other recruiting trials for Placenta Accreta

Currently open trials in the same condition.

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04911322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing